TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been given an average rating of "Buy" by the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued a report on the stock in the last year is $7.80.
A number of brokerages recently commented on TCRX. HC Wainwright decreased their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wedbush reissued an "outperform" rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and issued a $9.00 target price on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Barclays cut their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Finally, Wall Street Zen cut shares of TScan Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.
Get Our Latest Research Report on TScan Therapeutics
TScan Therapeutics Stock Performance
Shares of TCRX traded up $0.01 during mid-day trading on Friday, hitting $1.54. 450,410 shares of the company's stock were exchanged, compared to its average volume of 417,208. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.15. TScan Therapeutics has a 52 week low of $1.02 and a 52 week high of $7.89. The stock's 50-day simple moving average is $1.46 and its 200-day simple moving average is $2.07. The firm has a market cap of $87.15 million, a price-to-earnings ratio of -1.41 and a beta of 0.98.
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative return on equity of 55.76% and a negative net margin of 2,974.08%. On average, equities research analysts expect that TScan Therapeutics will post -1.12 EPS for the current year.
Insiders Place Their Bets
In related news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were purchased at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the completion of the transaction, the insider now directly owns 7,946,141 shares of the company's stock, valued at approximately $9,535,369.20. This represents a 17.79% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 4.35% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. SG Americas Securities LLC grew its position in TScan Therapeutics by 31.2% during the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock worth $62,000 after acquiring an additional 4,852 shares during the last quarter. Tocqueville Asset Management L.P. grew its holdings in shares of TScan Therapeutics by 26.8% during the fourth quarter. Tocqueville Asset Management L.P. now owns 260,870 shares of the company's stock worth $793,000 after purchasing an additional 55,140 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of TScan Therapeutics during the fourth quarter worth about $32,000. JPMorgan Chase & Co. increased its stake in shares of TScan Therapeutics by 109.9% in the fourth quarter. JPMorgan Chase & Co. now owns 66,756 shares of the company's stock valued at $203,000 after buying an additional 34,951 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of TScan Therapeutics by 5.2% in the fourth quarter. Wellington Management Group LLP now owns 132,895 shares of the company's stock valued at $404,000 after buying an additional 6,550 shares during the period. 82.83% of the stock is currently owned by institutional investors.
About TScan Therapeutics
(
Get Free ReportTScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Featured Articles
Before you consider TScan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.
While TScan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
